Screener
IBB vs BMED
iShares Biotechnology ETF vs iShares Health Innovation Active ETF
Key differences
- IBB costs 0.11% less per year.
- IBB is significantly larger than BMED — larger funds tend to be more liquid and less likely to close.
- IBB follows a index tracking strategy; BMED uses active selection.
- Over the last 3 years, IBB has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IBB | BMED | |
|---|---|---|
| Annual cost (TER) | 0.44% | 0.55% |
| Fund size (AUM) | $7.9B | $10M |
| Since | 2001 | 2020 |
| Dividend yield | 0.23% | 0.00% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | active selection |
| CAGR 1Y | +39.0% | +18.0% |
| CAGR 3Y | +9.6% | +4.9% |
| CAGR 5Y | +2.7% | +0.1% |
| Sharpe 3Y | 0.38 | 0.16 |
| Volatility 1Y | 19.75% | 14.94% |
| Max drawdown | -39.82% | -36.44% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IBB and BMED
Explore further